Parent Company


The hospital is an offshoot of the mainstream pharmaceutical and biotechnology venture, Panacea Biotec Ltd, a pioneer in its domain. Panacea Biotec is looked up to as a leader in health management, world over. Panacea Biotec is involved in research, manufacturing, export and marketing of branded pharmaceutical formulations, vaccines and biosimilars. With an annual turnover of USD $ 225 million, Panacea Biotec features amongst the finest 50 pharmaceutical companies of India with significant domestic & international presence. The organization is strengthened with an outstanding team of about 3200 highly committed employee base and 300 adroit scientists.

Here, scientists conceptualize breakthrough innovations at four state-of-the-art R&D centers in New Delhi, Navi Mumbai, Lalru and Mohali in Punjab. Our cutting-edge facilities meet the highest international standards, and comply with international regulatory requirements of US FDA, UK MHRA, MCC (South Africa) and WHO. Panacea Biotec has already made substantial headway in the international markets. With long-term strategies in place and an unwavering focus on innovation, we are continually pursuing the strategic quest to become a leading healthcare organization with a powerful global presence.

To remain competitive in such a scenario, Panacea Biotec is continuously following the strategy to introduce brands of international quality. As a result Panacea Biotec today enjoys a commanding position amongst the Pharmaceutical Companies in India. Panacea Biotec consistent efforts and performance has been acknowledged by numerous independent rating and survey agencies:

  • Panacea Biotec has achieved 313th rank among Pharmaceutical companies of India in Prescription Audit (as per CMARC- Mar.’04) and 42nd rank as per ORG IMS (MAT March’2004). Both ORG and CMARC are the leading independent market research companies in India.

  • Company is ranked 2nd amongst the biotechnology companies in India. (Source Biospectrum, Vol.-1, Issue September, 2003). Panacea Biotec has been placed amongst ”India’s most valuable companies” and “India’s biggest wealth creators”. (Source The min BT.Stern ranking of Companies, published in Business Today, 2004 issue).

  • Company features among India’s 500 Companies, 2003, a high profile reference compendium on prestigious Indian companies, published by the world renowned analyst, Dun & Bradstreet (D&B).

Contributions for development of

Biotechnology & Vaccines Sector

As a part of continuous thrust on development of biotechnology sector in India, Panacea Biotec has been actively involved in various activities in co. ordination with various industry chambers, governments and academic & research Organizations. In recognition of

Leadership qualities and significant contributions made by Dr. Rajesh Jain, Joint managing Director of Panacea Biotec in biotechnology sector, he has been appointed as Chairman, Biotechnology National committee of CII.


  • Panacea Biotec is the 2nd largest Vaccine producer in India

  • 3rd largest Biotechnology Company in India (ABLE Survey 2009)

  • Panacea Biotec has been pre-qualified by WHO to supply Oral Polio, Hepatitis B, Ecovac4 (DTwP-Hep B), Easyfour (DTwP-Hib) and Easyfive (DTwP-Hep B-Hib) Vaccines

  • First Indian company to develop and launch innovative combination vaccines viz. Ecovac4, Easyfour and Easyfive in India.

  • Ranked 48th amongst Pharmaceutical Companies in India (ORG IMS MAT March’09)

  • Pharmaceutical and Biotechnology formulation facility at Baddi certified as cGMP compliant by various regulatory authorities including the German Regulatory Authority and ANVISA (Brazil).

  • 26 product patents valid in more than 60 countries world wide

  • 1,158 patent applications filed, 325 granted/accepted for grant globally as on 31.03.2009.

  • Company’s Products reach more than 75 countries globally

  • Played a key role in eradicating polio by supplying more than 6 billion doses of Oral Polio Vaccine to Govt. of India & UNICEF.

  • Millions of patients enjoying happy & healthy life through our well established brands in niche therapeutic areas like pain management, diabetes management, organ transplant.

  • Stupendous contribution to Shareholders’ value

  • Continuous investment in Research & Development activities – around 14% of net turnover invested during fiscal 2009.

  • Over 260 Scientists working in 5 state-of-the art R&D Centers.

  • A family of around 3,600 people working relentlessly on improving quality of life of billions of people across the globe.

  • Dr. Rajesh Jain, JMD joined the rank of  top 40 most influential people in global pharmaceutical  industry in recognition for his vision and focus on prevention through vaccines and its delivery mechanism (source: World Pharmaceutical Frontiers, April 2008).

  • One of the 13 Indian Companies and 68th amongst top 100 fastest growing small & mid-sized companies in Asia as per survey by Business Week, US (Source: Business Standard, Nov. 2007).

  • In 2007-08 the Company has been granted a patent from US Patent & Trademark Office for their product ThankGod TM  (Euphorbia Prostrata) for effective management of hamorrhoids & piles (Patent No. 7,371,412 B2). With this, the Company is looking forward to launch this product in high potential markets of US and EU.

  • Panacea Biotec has around 300 scientists working in 5 state-of-the-art R&D Centers.

  • Launch of PacliALL which promises to provide the ultimate solution to the unmet needs of cancer patients.